| typ : |
Czasopismo |
| link internetowy : |
http://www.currenttherapeuticres.com/article/S0011-393X(15)00016-8/abstract |
|
| Zespoły badawcze : |
San Francisco - Theravance Biopharma |
| Autorzy : |
Gu Z, Parra C, Wong A, Nguyen A, Cheung R, Catalano T. |
| Tytuł : |
Post-reconstitution Stability of Telavancin with Commonly Used Diluents and Intravenous Infusion Solutions. |
| Numer : |
Current Ther Res ; 77: 105-110. 2015 |
|
| Poziom wiarygodności : |
|
| stabilność fizyczną : |
|
| Stabilność chemiczna : |
|
| Inne metody : |
|
| Komentarze : |
| Produkty rozpadu zidentyfikowane i oznaczone ilościowo |
|
Listy
 Telavancin hydrochloride
|
 |
 |
 |
 |
15 mg/ml |
2-8°C |
 |
| 7 |
 |
|
|
|
|
|
15 mg/ml |
20-25°C |
 |
| 12 |
 |
|
|
|
|
 |
15 mg/ml |
2-8°C |
|
| 7 |
|
|
|
|
|
|
15 mg/ml |
20-25°C |
|
| 12 |
|
|
|
|
 |
|
0.6 mg/ml |
2-8°C |
|
| 7 |
|
|
|
|
|
|
0.6 mg/ml |
20-25°C |
|
| 12 |
|
|
|
|
|
|
8 mg/ml |
2-8°C |
|
| 7 |
|
|
|
|
|
|
8 mg/ml |
20-25°C |
|
| 12 |
|
|
|
|
|
 |
0.6 mg/ml |
2-8°C |
|
| 7 |
|
|
|
|
|
|
0.6 mg/ml |
20-25°C |
|
| 12 |
|
|
|
|
|
|
8 mg/ml |
2-8°C |
|
| 7 |
|
|
|
|
|
|
8 mg/ml |
20-25°C |
|
| 12 |
|
|
|
|
|
